Ear-Seizure Detection (EarSD) Study

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorFelicia Chu

About this trial

The proposed study is an investigator-initiated study that aims to measure the accuracy of a wearable seizure detection and prediction device (Ear-Seizure Detection Device (EarSD)) by simultaneous recording with conventional video-EEG (Electroencephalogram) on patients with epileptic seizures in the Epilepsy Monitoring Unit of the hospital.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age ≥ 18 years.

Patients admitted to UMass Memorial Epilepsy Monitoring Unit (EMU) for long term video-EEG monitoring as part of standard care of both focal and generalized epilepsy.

Willing to wear the wearable device.

Ability to provide informed consent

Disqualifiers

Subjects wearing other ear devices such as hearing aids.

Inability or unwillingness to provide informed consent.

Irritation of the skin where the device is to be placed.

Patients with intracranial electrodes placement.

Trial design

Design model

Single group

Treatments tested in this trial

  • Ear-SD

    Device

    The Ear-SD is a purely EEG recording device Continuous Electroencephalogram (cEEG), Electromyogram (EMG), Electrooculogram (EOG), Photoplethysmogram (PPG), Electrodermoactivity (EDA), and Inertial Measurement Unit (IMU). The Ear-SD device rests on the ears and connects to the scalp by two sticker electrodes.

  • Electroencephalogram

    Diagnostic test

    Standard 21-channel scalp-continuous electroencephalogram (cEEG) with video recording and electrocardiogram (ECG)

Treatment groups

40 Participants
are divided into 1 treatment group
Group A: Ear-Worn GroupExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Seizure Recording Criteria 1

Recordings of Bioelectrical signal of subjects with the wearable device and simultaneous continuous EEG data is collected for the duration of hospitalization of participants. Outcome measures reported include number of seizure events per participant.

Time frame
Through study completion, an average of 7 Days
2

Seizure Recording Criteria 2

Recordings of Bioelectrical signal of subjects with the wearable device and simultaneous continuous EEG data is collected for the duration of hospitalization of participants. Outcome measures reported include average duration of each seizure in minutes and seconds and total recording time in hours aggregated to arrive at one reported value seizure classification.

Time frame
Through study completion, an average of 7 Days
3

Seizure Recording Criteria 3

Recordings of Bioelectrical signal of subjects with the wearable device and simultaneous continuous EEG data is collected for the duration of hospitalization of participants. Outcome measures reported include reported value seizure classification. Seizure classification includes Unclassified (UC), Focal Onset Aware (FOA), Focal Onset Impaired (FOIA), Focal to Bilateral Tonic-Clonic (FBTC).

Time frame
Through study completion, an average of 7 Days
4

Data Interpretation

EarSD extracted EEG signals from the log file plotted alongside EDF files from cEEG are measured and compared to detect seizure onset and offset times for data interpretation. Two-minute segments of cEEG European Data Format (EDF) consisting of non-seizure signals from periods before and after the seizures, and non-seizure signals from periods of daily activities like talking, eating, and walking are involved in the comparison to detect seizure onset and offset times. Prediction measurement of Seizure Sensitivity (SS) and False Positivity Rate per hour (FPR/h) are measured from the recorded data signals. Seizure Sensitivity (SS) is the ratio between the (number of predicted seizures)/(total number of seizures) = (number of true alarms)/(total number of seizures). FPR/h is the number of alarms that do not correspond to seizures raised in one hour. FPR/h = ((Number of false alarms/Interictal Duration) - (Number of False Alarms × Refractory period)).

Time frame
up to 2 years

Secondary outcomes

1

Qualitative Satisfaction Survey

At the end of the study, patients' experience and perception of the EarSD device are collected using a paper-based 7-question survey measured on a 5-point Likert scale ranging from Strongly Disagree to Strongly Agree. A maximum total point score of 35 represents a better reported satisfactory score from participants and having a good experience with the device and its comfortability for daily activities. The survey is a self-administered report, and participants will be asked about the comfortability and perceived utility of the device.

Time frame
Through study completion, an average of 7 Days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Felicia Chu

Lead sponsor

University of Massachusetts, Worcester

Sponsor institution

University of Massachusetts, Amherst

Collaborator